GLP-1 Medicine Use in Texas Medicare, 2019 to 2024
By Innovare Tx Regenerative & Wellness Clinic · Published November 12, 2026 · Public data, not medical advice
Medicare Part D claims for GLP-1 medicines written by Texas prescribers rose from 392,341 in 2019 to 1,811,427 in 2024, 4.6 times as many, and Part D drug costs for them reached $2.39 billion in 2024 before manufacturer rebates. Semaglutide and tirzepatide made up 84% of the 2024 claims.
These counts are FDA-approved GLP-1 medicines (brand-name and generic) filled through Medicare Part D. Compounded semaglutide and compounded tirzepatide, which some clinics including ours prescribe, are prepared by state-licensed compounding pharmacies, are not FDA approved, and are not counted here. This page reports public data; it is not medical advice.
Key numbers
- Part D claims for GLP-1 medicines by Texas prescribers in 2024, up from 392,341 in 2019
- 1,811,427Part D claims for GLP-1 medicines by Texas prescribers in 2024, up from 392,341 in 2019Source: CMS Part D Prescribers by Geography and Drug, 2019 and 2024
- Part D drug costs for those claims in 2024, before manufacturer rebates (2019: $467.3 million)
- $2.39 billionPart D drug costs for those claims in 2024, before manufacturer rebates (2019: $467.3 million)Source: CMS Part D Prescribers by Geography and Drug, 2024
- claims per 1,000 Texans enrolled in Part D in 2024, against 401.4 nationally (20% higher)
- 482.7claims per 1,000 Texans enrolled in Part D in 2024, against 401.4 nationally (20% higher)Source: CMS Part D Prescribers by Geography and Drug; CMS Medicare Monthly Enrollment, 2024
- Texas's rank on that rate among the 50 states and DC in 2024 (highest: Louisiana, 640.1)
- 10th of 51Texas's rank on that rate among the 50 states and DC in 2024 (highest: Louisiana, 640.1)Source: Same, our calculation
- share of the 2024 Texas claims for semaglutide or tirzepatide (1,515,200 claims, $1.98 billion)
- 84%share of the 2024 Texas claims for semaglutide or tirzepatide (1,515,200 claims, $1.98 billion)Source: CMS Part D Prescribers by Geography and Drug, 2024
- Texas
- United States
Texas = claims written by prescribers whose practice address is in Texas, divided by Texans enrolled in Part D.
| Year | Texas claims | Texas drug costs | Texas per 1,000 enrollees | Semaglutide + tirzepatide share (TX) | U.S. claims | U.S. drug costs | U.S. per 1,000 enrollees |
|---|---|---|---|---|---|---|---|
| 2019 | 392,341 | $467.3 million | 129.1 | 11.6% | 4,798,441 | $5.27 billion | 104.7 |
| 2020 | 491,690 | $637.9 million | 154.9 | 23.0% | 6,050,528 | $7.26 billion | 127.6 |
| 2021 | 609,879 | $862.3 million | 185.4 | 34.0% | 7,720,930 | $10.01 billion | 158.2 |
| 2022 | 802,580 | $1.19 billion | 234.7 | 46.7% | 10,156,055 | $13.91 billion | 201.9 |
| 2023 | 1,347,951 | $1.96 billion | 379.4 | 68.1% | 16,229,271 | $22.20 billion | 312.7 |
| 2024 | 1,811,427 | $2.39 billion | 482.7 | 83.6% | 21,825,833 | $27.50 billion | 401.4 |
| Medicine | Claims, 2024 | Share of claims | Drug costs, 2024 | Claims, 2019 |
|---|---|---|---|---|
| Semaglutide | 1,023,411 | 56.5% | $1.35 billion | 45,658 |
| Tirzepatide | 491,789 | 27.1% | $624.0 million | none |
| Dulaglutide | 262,491 | 14.5% | $368.7 million | 167,838 |
| Liraglutide | 14,711 | 0.8% | $14.6 million | 126,656 |
| Exenatide | 19,025 | 1.1% | $27.8 million | 52,163 |
Download the data (CSV) · Free to reuse under CC BY 4.0 with credit to Innovare Tx Regenerative & Wellness Clinic.
What the data show
- Texas prescribers' GLP-1 claims in 2024 were 4.6 times their 2019 level; nationally, 4.5 times.
- The biggest jump came in 2023, when Texas claims rose from 802,580 to 1,347,951. Tirzepatide, which first appears in the data in 2022, went from 13,197 Texas claims that year to 491,789 in 2024.
- Texas prescribers wrote 8.3% of all U.S. Part D GLP-1 claims in 2024, while Texas had 6.9% of Part D enrollees.
- 79.5% of the 2024 Texas claims were for enrollees aged 65 and older; the rest were for enrollees under 65, who qualify for Medicare through a disability or kidney failure.
What this means if you are thinking about medical weight management
- GLP-1 medicines are far more common in Texas Medicare than they were five years ago: about 482.7 claims per 1,000 Part D enrollees in 2024, against 129.1 in 2019.
- In 2024, Medicare Part D could not cover a drug used for weight loss alone. Federal law lets Part D leave out "agents when used for anorexia, weight loss, or weight gain" (42 U.S.C. 1396r-8(d)(2)(A), applied to Part D by 42 U.S.C. 1395w-102(e)(2)). The claims counted here were paid for uses Part D could cover, such as type 2 diabetes. In March 2024 the FDA approved one semaglutide product to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight.
- Coverage has changed since 2024. CMS runs the Medicare GLP-1 Bridge, a short-term program that gives eligible Part D enrollees access to certain GLP-1 drugs for weight management between July 1, 2026, and December 31, 2027 (CMS memo, June 10, 2026). Ask your plan what applies to you.
- Drug cost figures are totals paid by plans, patients and other payers before manufacturer rebates. They are not what any one patient pays.
- Whether any weight management medicine fits you is a medical decision made after an evaluation. Our weight management program starts with a visit and lab work, and we explain the options, including what is and is not FDA approved.
Method
We downloaded every row of the CMS Medicare Part D Prescribers by Geography and Drug dataset for 2019 through 2024 whose generic name is a single-ingredient GLP-1 medicine: semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, lixisenatide and albiglutide. Tirzepatide acts on both the GIP and GLP-1 receptors; we include it because it is prescribed for the same uses. Combination products that pair a GLP-1 medicine with insulin are not included.
A claim is one prescription fill or refill. Texas means claims written by prescribers whose practice address in the national provider registry (NPPES) is in Texas, wherever the patient lives. U.S. figures are the dataset's national rows.
Drug costs are the dataset's total drug cost, which the CMS data dictionary for this dataset defines this way: "This amount includes ingredient cost, dispensing fee, sales tax, and any applicable vaccine administration fees". It is paid by the Part D plan, the patient, government subsidies and other payers. The CMS methodology notes that "these total drug costs do not reflect any manufacture rebates".
Rates divide claims by the number of people enrolled in Part D in that year, from CMS Medicare Monthly Enrollment (annual figures). The state ranking uses the same rate for the 50 states and the District of Columbia.
CMS publishes figures for each product, brand-name and generic; we added the products of each medicine together and do not name the brands. The scripts and raw files are in the site's code repository, and every figure on this page is computed by them.
Limits
- CMS leaves out rows with fewer than 11 claims, so a few very small products in a state can be missing. The effect on the totals is tiny.
- Part D covers people in stand-alone drug plans and in Medicare Advantage plans with drug coverage. It does not show prescriptions paid in cash, through employer plans or through Medicaid alone.
- Claims do not say why a medicine was prescribed, and the data do not show how many different people filled a GLP-1 prescription across all medicines.
- Prescriber location and patient residence can differ, for example for patients who live near a state line or move during the year.
Sources
- CMS, Medicare Part D Prescribers - by Geography and Drug. Data years 2019 to 2024 (2024 data released May 2026).
- CMS, Medicare Monthly Enrollment. Annual figures, 2019 to 2024 (release with data through July 2026).
- CMS, Medicare Part D Prescribers methodology. April 2026.
- CMS, Medicare Part D Prescribers by Geography and Drug data dictionary (source of the drug cost definition). April 2025.
- 42 U.S.C. 1395w-102(e)(2) and 1396r-8(d)(2)(A). Current text.
- FDA press announcement, new cardiovascular indication. March 8, 2024.
- CMS, Medicare GLP-1 Bridge: Expectations and FAQs for Part D Sponsors. June 10, 2026.
Cite this study
Innovare Tx Regenerative & Wellness Clinic. "GLP-1 Medicine Use in Texas Medicare, 2019 to 2024." November 12, 2026. https://innovaretx.com/research/glp1-use-texas-medicare. Data: CMS Medicare Part D Prescribers by Geography and Drug.
The table above is available as a CSV file under a Creative Commons Attribution 4.0 license. Questions about the data: contact@innovaretx.com.
More from our research and data section · Related: Medical weight management
Also in our research: Obesity and Arthritis Across Dallas-Fort Worth Cities · Knee and Joint Injections in Medicare: Texas vs the U.S., 2019 to 2024 · Weight and Joint Health Statistics: Dallas-Fort Worth
Questions about medical weight management?
Book a visit at our Addison clinic. We start with an evaluation and lab work, then explain your options, including what is and is not FDA approved.